![]() |
市场调查报告书
商品编码
1662647
2030 年碘化钾市场预测:按类型、形式、等级、应用和地区进行的全球分析Potassium Iodide Market Forecasts to 2030 - Global Analysis By Type (Solid, Liquid, and Other Types), Form, Grade, Application and By Geography |
根据 Stratistics MRC 的数据,全球碘化钾市场预计 2024 年将达到 10.6718 亿美元,到 2030 年将达到 18.396 亿美元,复合年增长率为 9.5%。
碘化钾(KI)是由钾和碘组成的化合物。碘化钾常用于医疗、工业和食品领域。在医学上,它主要用于预防碘缺乏症和在辐射紧急情况下保护甲状腺。在食品工业中,将碘化钾添加到食盐中製成碘盐,有助于预防碘缺乏症。此外,它们还可用于化学合成、摄影和作为实验室试剂。
根据世界卫生组织(WHO)统计,全球约有18亿人患有碘缺乏症。根据国际组织报告,全球有超过10%的人口无法获得碘盐。
碘缺乏情况加剧
缺乏碘仍然是影响全球数百万人的主要公共卫生问题,特别是在缺乏富碘食物的地区。碘化钾作为可靠的碘来源,用于生产碘盐,对于预防碘缺乏症至关重要。为了解决碘缺乏问题,包括甲状腺功能障碍和发育障碍,政府和卫生组织提倡使用碘盐。随着人们对碘缺乏健康危害的认识不断提高,食品中对碘化钾的需求也不断增加。
副作用和过度使用问题
碘化钾市场的一个主要障碍是对副作用和滥用的担忧。儘管碘化钾能有效治疗碘缺乏症并保护甲状腺免受辐射照射,但如果使用不当或过量,可能会导致许多健康问题。长期过量摄取的碘会损害甲状腺功能并对健康产生不利影响。这些风险使得一些消费者和健康专家对使用碘化钾犹豫不决,特别是将其用作膳食补充剂或紧急情况。因此,严格的规定和剂量指南对于减少这些担忧至关重要。
不断扩张的製药业
碘化钾用于治疗多种甲状腺疾病,包括碘缺乏症、甲状腺肿和甲状腺功能亢进。碘化钾用于治疗各种甲状腺疾病,包括碘缺乏症、甲状腺肿和甲状腺功能亢进症,在辐射防护中也发挥重要作用,特别是在发生核电事故时。随着全球製药业因医疗需求的增加和治疗的进步而不断发展,药物对碘化钾的需求也不断增加。特别是医疗保健基础设施正在快速改善的新兴市场,为这一成长做出了贡献。此外,对碘化钾在癌症治疗和药物製剂等领域的新治疗应用的持续研究正在进一步推动市场扩张。
原物料价格波动
碘化钾生产的主要原料是碘,受供需失衡、地缘政治紧张局势及产能变化等因素影响,碘价格可能大幅波动。碘主要从盐水和海藻中提取,但某些地区的供应有限,且价格波动较大。原物料价格的波动直接影响碘化钾的生产成本,有可能提高市场价格并影响碘盐和药品的可负担性。因此,製造商可能面临维持价格稳定和盈利的挑战,这可能会阻碍市场成长。
COVID-19 的影响
COVID-19 疫情以多种方式影响了碘化钾市场。一方面,全球供应链中断,影响碘化钾生产与流通,导致部分地区出现供不应求。另一方面,疫情提高了公众的健康意识,包括对碘对维持甲状腺健康的重要性的认识,并导致对食品和药品用碘盐和碘化钾的需求增加。在疫情期间,对健康和保健的关注帮助市场復苏。
预计在预测期内,固态部分将成为最大的部分。
由于固体材料广泛应用于製药、食品製造和化学工业等各个领域,预计在预测期内固态材料将占据最大的市场占有率。固体碘化钾是製作碘盐的首选,因为它易于处理和储存。在医学上,它通常以锭剂或口服液形式用于治疗碘缺乏症和甲状腺疾病。此外,固体形式的稳定性和成本效益也使其在化学合成和其他工业程中得到越来越广泛的应用。
预计预测期内化学合成部门将以最高的复合年增长率成长。
由于化学合成领域在各种有机和无机化学反应中作为试剂的重要作用,预计在预测期内将呈现最高的成长率。碘化钾在化学工业中广泛用于生产碘基化合物、催化剂及中间体。碘化钾促进卤化和还原反应等过程,在药品、农药和其他特殊化学品的生产中至关重要。它的多功能性、有效性和提高反应效率的能力继续推动化学合成应用的需求。
由于印度和中国等国家对碘缺乏问题的认识不断提高以及碘盐的采用,预计亚太地区将在预测期内占据最大的市场占有率。该地区的製药和食品业正在扩大,进一步推动了医疗保健和食品强化对碘化钾的需求。此外,日本等拥有核能计画的国家对辐射安全的日益担忧也促进了市场的成长。经济发展、医疗保健服务的改善和政府措施也是推动该地区市场发展的关键因素。
预计北美地区在预测期内将呈现最高的复合年增长率。这是因为,食品中碘盐的使用量不断增加,推动了需求成长,尤其是在美国和加拿大。此外,製药业的成长,特别是基于碘的治疗,也促进了市场扩张。碘化钾对于紧急情况下的辐射防护也至关重要,因此在有核能设施的地区也采用它。强大的医疗保健基础设施和政府法规进一步推动北美市场的成长。
According to Stratistics MRC, the Global Potassium Iodide Market is accounted for $1067.18 million in 2024 and is expected to reach $1839.60 million by 2030 growing at a CAGR of 9.5% during the forecast period. Potassium iodide (KI) is a chemical compound made up of potassium and iodine. It is commonly used in medical, industrial, and food applications. In healthcare, it is primarily used to prevent iodine deficiency and protect the thyroid gland during radiation emergencies. In the food industry, potassium iodide is added to salt to create iodized salt, which helps prevent iodine deficiency. Additionally, it has applications in chemical synthesis, photography, and as a reagent in laboratory experiments.
According to the World Health Organization, an approximated 1.8 billion people worldwide have iodine deficiency. The report by the international agency also states that more than 10 of the world's population do not have access to iodized salt.
Rising incidence of iodine deficiency
Iodine deficiency continues to be a major public health concern that affects millions of people worldwide, especially in areas with restricted access to iodine-rich food sources. As a dependable source of iodine, potassium iodide which is mostly utilized in the manufacturing of iodized salt is essential in resolving this insufficiency. In order to address iodine deficient illnesses, including thyroid dysfunction and developmental problems, governments and health groups have been advocating for the usage of iodized salt. The need for potassium iodide in food products is rising as people become more conscious of the health hazards linked to iodine shortage.
Side effects and overuse concerns
Significant barriers to the potassium iodide market include side effects and worries about misuse. Despite its effectiveness in treating iodine deficiency and shielding the thyroid from radiation exposure, potassium iodide can cause a number of health issues if used incorrectly or in excess. Excessive iodine consumption over time can interfere with thyroid function and have negative health effects. Some consumers and medical experts are hesitant to use potassium iodide because of these hazards, especially in areas where it is utilized as a supplement or in emergency situations. Therefore, stringent regulation and dose guidelines are essential to reducing these worries.
Expanding pharmaceutical industry
Potassium iodide is used in the treatment of various thyroid disorders, including iodine deficiency, goiter, and hyperthyroidism. It also plays a crucial role in radiation protection, particularly in cases of nuclear accidents. As the global pharmaceutical industry grows, driven by increasing healthcare needs and advancements in medical treatments, the demand for potassium iodide in pharmaceuticals continues to rise. Emerging markets, where healthcare infrastructure is rapidly improving, are particularly contributing to this growth. Furthermore, ongoing research into new therapeutic applications of potassium iodide in areas such as cancer treatment and drug formulations further fuels the market's expansion.
Fluctuations in raw material prices
The primary raw material for potassium iodide production is iodine, and its price can be highly volatile due to factors such as supply-demand imbalances, geopolitical tensions, and changes in production capabilities. Iodine is primarily extracted from brine and seaweed, and its limited supply from specific regions makes it susceptible to price volatility. These fluctuations in raw material prices directly impact the cost of potassium iodide production, potentially increasing market prices and affecting the affordability of iodized salt and pharmaceutical products. As a result, manufacturers may face challenges in maintaining price stability and profitability, which can hinder market growth.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the potassium iodide market. On one hand, the disruption in global supply chains affected the production and distribution of potassium iodide, leading to shortages in some regions. On the other hand, the pandemic heightened awareness about public health, including the importance of iodine in maintaining thyroid health, drives increased demand for iodized salt and potassium iodide in food and pharmaceutical applications. The focus on health and wellness during the pandemic contributed to the market's recovery.
The solid segment is expected to be the largest during the forecast period
The solid segment is expected to account for the largest market share during the forecast period, due to its widespread use in various applications, including pharmaceuticals, food production, and chemical industries. Solid potassium iodide is preferred in manufacturing iodized salt, as it is easier to handle and store. In pharmaceuticals, it is commonly used in the form of tablets or oral solutions for treating iodine deficiency and thyroid disorders. Additionally, the solid form's stability and cost-effectiveness contribute to its increasing adoption in chemical synthesis and other industrial processes.
The chemical synthesis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the chemical synthesis segment is predicted to witness the highest growth rate, owing to its essential role as a reagent in various organic and inorganic chemical reactions. It is widely used in the production of iodine-based compounds, catalysts, and intermediates in the chemical industry. Potassium iodide facilitates processes like halogenation and reduction reactions, making it indispensable in the manufacture of pharmaceuticals, agrochemicals, and other specialty chemicals. Its versatility, effectiveness, and ability to enhance reaction efficiency continue to fuel its demand in chemical synthesis applications.
During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by the increasing awareness of iodine deficiency and the adoption of iodized salt in countries like India and China. The region's expanding pharmaceutical and food industries further fuel demand for potassium iodide in healthcare and food fortification. Additionally, growing concerns about radiation safety in countries with nuclear energy programs, such as Japan, contribute to the market's growth. Economic development, improved healthcare access, and government initiatives are also key factors driving the market in the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the increasing use of iodized salt in food products, especially in the U.S. and Canada, supports demand. Additionally, the pharmaceutical industry's growth, particularly for iodine-based treatments, contributes to market expansion. Potassium iodide is also crucial for radiation protection in emergency situations, boosting its adoption in regions with nuclear facilities. Strong healthcare infrastructure and government regulations further drive market growth in North America.
Key players in the market
Some of the key players profiled in the Potassium Iodide Market include Nippon Chemical Industrial Co., Ltd., Iochem Corporation, ABCR GmbH & Co. KG, Merck Group, Fisher Scientific, PVS Chemicals, Inc., Tianjin Zhonglian Pharmaceutical Co., Ltd., Sisco Research Laboratories Pvt. Ltd., Shandong Lianmeng Chemical Group Corporation, Hubei Xinjing Science and Technology Co., Ltd., Avidity Science, BASF SE, Jiangsu Jiamai Technology Co., Ltd., Zhejiang Xinxin Chemical Industry Co., Ltd., and Lianyungang Yizhou Pharmaceutical Co., Ltd.
In January 2025, Merck acquires HUB organoids holding b.v., expands next-gen biology portfolio. Merck announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions.
In June 2023, Tianjin Tianyao Pharmaceuticals Co.,Ltd. announced that it had received the Notice of Approval for the Launching Application of Chemical APIs for Travoprost approved and issued by National Medical Products Administration, and the preparation corresponding to Travoprost was mainly Travoprost eye drops.
In November 2021, Thermo Fisher Scientific introduced a new line of potassium iodide powder for laboratory and industrial applications, including chemical synthesis and other production processes.